{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:51:20Z","timestamp":1793839880702,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004219","name":"Paul Scherrer Institut","doi-asserted-by":"publisher","award":["17\/05\/2012"],"award-info":[{"award-number":["17\/05\/2012"]}],"id":[{"id":"10.13039\/501100004219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004219","name":"Paul Scherrer Institut","doi-asserted-by":"publisher","award":["WO 2016\/027273 19\/08\/2015"],"award-info":[{"award-number":["WO 2016\/027273 19\/08\/2015"]}],"id":[{"id":"10.13039\/501100004219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004219","name":"Paul Scherrer Institut","doi-asserted-by":"publisher","award":["WO\/2015\/104711 08\/01\/2015"],"award-info":[{"award-number":["WO\/2015\/104711 08\/01\/2015"]}],"id":[{"id":"10.13039\/501100004219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004219","name":"Paul Scherrer Institut","doi-asserted-by":"publisher","award":["WO2012\/156969"],"award-info":[{"award-number":["WO2012\/156969"]}],"id":[{"id":"10.13039\/501100004219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.annonc.2022.03.012","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:43:22Z","timestamp":1648039402000},"page":"720-727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Phase II single-arm study of nivolumab and ipilimumab (Nivo\/Ipi) in\u00a0previously treated classical Kaposi sarcoma (cKS)"],"prefix":"10.1016","volume":"33","author":[{"given":"A.","family":"Zer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Icht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Yosef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Avram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Jacobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Peretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Merimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ben-Ami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Shapira Frommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"Schwarzbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bernstine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Weitzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Vornicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bar-Sela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Stemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5192","key":"10.1016\/j.annonc.2022.03.012_bib1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.012_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/bjc.1994.370","article-title":"Epidemiological characteristics of Kaposi\u2019s sarcoma prior to the AIDS epidemic","volume":"70","author":"Kaldor","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2022.03.012_bib3","doi-asserted-by":"crossref","first-page":"101876","DOI":"10.1016\/j.canep.2020.101876","article-title":"Sarcoma incidence and subtype distribution in Israel - A population-based study","volume":"70","author":"Icht","year":"2020","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"10.1016\/j.annonc.2022.03.012_bib4","first-page":"1097","article-title":"Tailoring treatment for classical Kaposi\u2019s sarcoma: comprehensive clinical guidelines","volume":"14","author":"Brenner","year":"1999","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.012_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2004.08.064","article-title":"Highly active antiretroviral therapy in AIDS-associated Kaposi\u2019s sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi\u2019s sarcoma","volume":"22","author":"Krown","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.012_bib6","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/1097-0142(19941115)74:10<2873::AID-CNCR2820741021>3.0.CO;2-1","article-title":"Mediterranean Kaposi\u2019s sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine","volume":"74","author":"Brambilla","year":"1994","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.012_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1468-3083.2007.02405.x","article-title":"Radiotherapy of classic and human immunodeficiency virus-related Kaposi\u2019s sarcoma: results in 1482 lesions","volume":"22","author":"Caccialanza","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.012_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1346-8138.2002.tb00198.x","article-title":"Chemotherapy of disseminated cutaneous classic Kaposi\u2019s sarcoma with vinblastine","volume":"29","author":"Turk","year":"2002","journal-title":"J\u00a0Dermatol"},{"issue":"6","key":"10.1016\/j.annonc.2022.03.012_bib9","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/sj.jid.5701215","article-title":"Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi\u2019s sarcoma: a multicenter study","volume":"128","author":"Di Lorenzo","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.012_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archderm.1996.03890270061008","article-title":"Long-term follow-up of non-HIV Kaposi\u2019s sarcoma treated with low-dose recombinant interferon alfa-2b","volume":"132","author":"Costa da Cunha","year":"1996","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.012_bib11","first-page":"175","article-title":"(18)F-FDG PET\/CT findings in a case with HIV (-) Kaposi sarcoma","volume":"33","author":"Ozdemir","year":"2014","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.012_bib12","first-page":"78","article-title":"18F-FDG PET\/CT findings in an HIV-infected patient with systemic Kaposi sarcoma","volume":"131","author":"Yin","year":"2021","journal-title":"Pol Arch Intern Med"},{"issue":"24","key":"10.1016\/j.annonc.2022.03.012_bib13","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.annonc.2022.03.012_bib14","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1002\/cncr.25362","article-title":"Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy","volume":"116","author":"Cianfrocca","year":"2010","journal-title":"Cancer"},{"issue":"34","key":"10.1016\/j.annonc.2022.03.012_bib15","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","article-title":"Pomalidomide for symptomatic Kaposi\u2019s sarcoma in people with and without HIV infection: a phase I\/II study","volume":"34","author":"Polizzotto","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.012_bib16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2016-0486","article-title":"A\u00a0phase Ib study of sorafenib (BAY 43-9006) in patients with Kaposi sarcoma","volume":"22","author":"Uldrick","year":"2017","journal-title":"Oncologist"},{"issue":"10231","key":"10.1016\/j.annonc.2022.03.012_bib17","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(19)33222-2","article-title":"Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial","volume":"395","author":"Krown","year":"2020","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.annonc.2022.03.012_bib19","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2003.10.162","volume":"21","author":"Nasti","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.03.012_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2018.12.036","article-title":"Diagnosis and treatment of Kaposi\u2019s sarcoma: European consensus-based interdisciplinary guideline (EDF\/EADO\/EORTC)","volume":"114","author":"Lebbe","year":"2019","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2022.03.012_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2022.03.012_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imm.13285","article-title":"Recent developments in immunotherapy of cancers caused by human papillomaviruses","volume":"163","author":"Fakhr","year":"2021","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.annonc.2022.03.012_bib23","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2022.03.012_bib24","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2022.03.012_bib25","article-title":"1077MO - PD1 blockade with pembrolizumab in classic and endemic Kaposi sarcoma: a multicenter phase II study","volume":"2020","author":"Delyon","year":"2020","journal-title":"ESMO Virtual Congress"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.012_bib26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/cup.13716","article-title":"Stage-related PD-L1 expression in Kaposi sarcoma tumor microenvironment","volume":"47","author":"Joest","year":"2020","journal-title":"J\u00a0Cutan Pathol"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.012_bib27","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1007\/s12325-019-01051-z","article-title":"Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors","volume":"36","author":"Arora","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.annonc.2022.03.012_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918815598","article-title":"Gene code CD274\/PD-L1: from molecular basis toward cancer immunotherapy","volume":"10","author":"Fabrizio","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2022.03.012_bib29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41579-018-0064-6","article-title":"Molecular mechanisms of viral oncogenesis in humans","volume":"16","author":"Krump","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.012_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-019-0743-4","article-title":"Immune checkpoint inhibitors in the treatment of virus-associated cancers","volume":"12","author":"Gao","year":"2019","journal-title":"J\u00a0Hematol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342200391X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342200391X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:08:58Z","timestamp":1760335738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342200391X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S092375342200391X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.03.012","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II single-arm study of nivolumab and ipilimumab (Nivo\/Ipi) in\u00a0previously treated classical Kaposi sarcoma (cKS)","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}